Global Influenza Surveillance and Response System

Global Influenza Surveillance and Response System
Name	Global Influenza Surveillance and Response System
Formation	1952
Type	International public health network
Headquarters	Geneva
Region served	Worldwide
Parent organization	World Health Organization

Global Influenza Surveillance and Response System The Global Influenza Surveillance and Response System is an international network coordinating influenza surveillance, virus characterization, vaccine strain selection, and outbreak response. It links national influenza centers, regional reference laboratories, and public health institutions to inform policy decisions and vaccine composition. The System underpins seasonal influenza control, pandemic preparedness, and zoonotic influenza risk assessment across continents.

Overview

The System originated from postwar initiatives and was formalized under the auspices of World Health Organization leadership alongside collaboration with Pan American Health Organization, European Centre for Disease Prevention and Control, Centers for Disease Control and Prevention, and national ministries such as Ministry of Health (Japan), Public Health England, and China Center for Disease Control and Prevention. Foundational meetings involved actors linked to United Nations agencies, World Bank, and research institutions like Walter Reed Army Institute of Research and Rockefeller Foundation. It operates through a network model similar in scale to consortia such as Global Polio Eradication Initiative and Global Fund. Historic events shaping the System include responses to the 1957 influenza pandemic, 1968 influenza pandemic, 2009 swine flu pandemic, and outbreaks affecting regions like Southeast Asia, Sub-Saharan Africa, Eastern Europe, and Latin America.

Structure and Components

The System comprises National Influenza Centers, WHO Collaborating Centres, Essential Regulatory Laboratories, and H5 Reference Laboratories drawn from institutions including Institut Pasteur, Centers for Disease Control and Prevention, National Institute for Viral Disease Control and Prevention (China), London School of Hygiene & Tropical Medicine, and Karolinska Institutet. Governance involves advisory groups such as the Influenza Pandemic Preparedness Framework committees, technical working groups from Gavi, the Vaccine Alliance, and policy inputs from G20 health ministers and regional bodies like African Union health authorities. Laboratories interact with vaccine manufacturers such as Sanofi, GlaxoSmithKline, Moderna, Inc., and regulatory agencies including European Medicines Agency, U.S. Food and Drug Administration, and Medicines and Healthcare products Regulatory Agency. Data flows through surveillance platforms linked to Global Health Security Agenda partners and research networks like International Severe Acute Respiratory and Emerging Infection Consortium.

Surveillance Activities

Surveillance activities integrate sentinel surveillance, virologic sampling, and genomic sequencing conducted by institutions including University of Oxford, Johns Hopkins University, Peking University, and University of São Paulo. Field investigations have involved coordination with Centers for Disease Control and Prevention, Food and Agriculture Organization, and World Organisation for Animal Health on zoonotic transmission at interfaces like live markets in Wuhan and poultry farms in Vietnam. Reporting and analytics leverage bioinformatics hubs such as European Bioinformatics Institute, National Center for Biotechnology Information, and platforms used by Global Initiative on Sharing All Influenza Data collaborators. Epidemiologic studies reference cohorts assembled by Harvard T.H. Chan School of Public Health, Imperial College London, University of Melbourne, and clinical trial sites linked to National Institutes of Health. Regional surveillance priorities align with programs from African Centres for Disease Control and Prevention, Southeast Asia Regional Office, and Pan American Health Organization offices.

Virus Characterization and Vaccine Composition

Virus characterization uses antigenic and genetic analyses performed by WHO Collaborating Centres located at Centers for Disease Control and Prevention (United States), Francis Crick Institute, Tokyo Metropolitan Institute of Public Health, and National Institute for Medical Research laboratories. Sequence data from GISAID-affiliated researchers and bioinformatics contributions from Broad Institute and Sanger Institute inform vaccine strain selection discussed at biannual consultations involving experts from European Medicines Agency, Advisory Committee on Immunization Practices, National Institutes of Health, and manufacturers like AstraZeneca and Seqirus. The process considers evidence from clinical efficacy studies published by teams at Karolinska Institutet, McMaster University, Stanford University, and Kobe University and aligns with regulatory timelines set by World Trade Organization-linked trade health provisions and national licensure authorities.

Response and Pandemic Preparedness

Response frameworks build on lessons from the 2009 swine flu pandemic, coordination with United Nations Children's Fund, and emergency operations used during outbreaks in Mexico, India, Indonesia, and Bangladesh. Pandemic preparedness includes stockpiling strategies similar to initiatives by European Commission, surge laboratory capacity modeled on Defense Threat Reduction Agency deployments, and simulation exercises run with partners like Bill & Melinda Gates Foundation, USAID, and Coalition for Epidemic Preparedness Innovations. Clinical management guidance references protocols from World Health Organization emergency guidelines, treatment trials coordinated with Oxford Vaccine Group, and hospital preparedness planning from Mayo Clinic and Cleveland Clinic. Cross-sectoral One Health approaches engage Food and Agriculture Organization and World Organisation for Animal Health.

Capacity Building and Partnerships

Capacity building emphasizes training at centers such as Institut Pasteur, Pasteur Network, U.S. Naval Medical Research Center, and universities including University of Cape Town and Aga Khan University. Partnerships extend to philanthropic organizations like Wellcome Trust, multilateral funds including Global Fund, and bilateral cooperation with nations such as Japan, United States, United Kingdom, and Germany. Technology transfer and intellectual property discussions involve World Intellectual Property Organization frameworks, while surveillance financing engages stakeholders including Bill & Melinda Gates Foundation and Asian Development Bank. Collaborative research projects link to consortia like European Research Council grants and multinational clinical networks including INSIGHT.

Category:Public health